Description

Overview: PT-141 (Bremelanotide) 10 mg is a high-purity synthetic melanocortin receptor agonist peptide supplied in lyophilized (freeze-dried) powder form for laboratory research applications. It is a cyclic heptapeptide derived from the melanocortin system and is widely studied in controlled research settings for its activity on central nervous system pathways, particularly melanocortin receptors such as MC3R and MC4R. Research literature describes PT-141 as being investigated for its role in modulating neural signaling associated with sexual behavior, motivation pathways, and hypothalamic receptor activity. Unlike peripheral-acting compounds, it is primarily studied for its central (brain-mediated) mechanism of action in experimental models. Clinical references describe bremelanotide as an FDA-approved prescription medication (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, administered via subcutaneous injection under medical supervision. Each vial is manufactured under strict quality standards and labeled for Research Use Only (RUO). This product is strictly not intended to diagnose, treat, cure, or prevent any disease and is not approved for human or veterinary use. It is intended exclusively for qualified laboratory research purposes.